FDA Says No “Evidence” Exists Supporting Pfizer Claims

(NewsGlobal.com)- Pfizer’s Paxlovid pill used in patients with recurrent Covid-19 symptoms shows no benefit for a longer course of treatment, which is in direct opposition to the company’s CEO, Albert Bourla, who had previously stated that the drug was beneficial.

There are increasing cases of individuals taking Pfizer’s antiviral tablet getting another bout of Covid-19 shortly after recovering, leading doctors to be perplexed and question the medication’s effectiveness.

Whenever virus levels rise again, you administer another course, just like you would with antibiotics, and that’s it,” Pfizer CEO Albert Bourla said on Tuesday, according to the Wall Street Journal.

In a statement issued on Wednesday, the Food and Drug Administration discredited Pfizer’s top executive’s suggestion that patients can take extra Paxlovid tablets for repeated symptoms.

According to a U.S. Food and Drug Administration official, there is “no evidence” that the second course of Pfizer Inc.’s Paxlovid will help Covid-19 patients whose symptoms return after an initial dose of the antiviral. This data comes a day after Pfizer executives advocated for the idea in a conference call.

After many patient reports of viral recurrences following the completion of a five-day course of Paxlovid, physicians and viral specialists have been baffled as to why this has happened.

The second round of medication may be prescribed to patients who have a rebound effect, according to Pfizer Chief Executive Officer Albert Bourla, in an interview published on Tuesday.

Some doctors have indicated that taking Paxlovid for a more extended period may help avoid recurring symptoms.

According to John Farley, director of the Centers for Disease Control and Prevention, there is no evidence to suggest a lengthier course of therapy or two separate five-day treatments to treat or prevent a recurrence.

“We continue to examine data from clinical studies and give new information as soon as it becomes available,” said the company.

According to a Pfizer spokeswoman on Thursday, the Paxlovid emergency authorization label does not restrict a patient from being prescribed a second round of Paxlovid if the virus recurs after the initial course of medication is finished.

Last month, Pfizer issued a statement acknowledging that it had failed to lower the likelihood of proven and symptomatic COVID-19 infection in persons who had been exposed to the virus while living with someone who had been infected.

In a statement, Bourla said that while the results of this particular study were disappointing, they did not invalidate the favorable efficacy and safety data obtained in a previous trial for the treatment of COVID-19 patients at high risk of developing severe illness.